Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Molecular targets of FTY720 (fingolimod).
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom.
Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
Medical marijuana: clearing away the smoke.
A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
Progress in multiple sclerosis research in the last year.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
HERV-W envelope protein inhibits oligodendroglial precursor cell differentiation.
Benign Multiple Sclerosis: Does it exist?
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
Celiac disease and multiple sclerosis in the northwest of Iran.
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis.

Pages